SecBot SecBot
8-K ·Filed Nov 12, 2026

CTSO

Cytosorbents Corp
NEUTRAL
Impact 5/10
Horizonweeks Processed9d 14h ago SEC0000929638-26-004267
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The operating cash flow breakeven milestone reduces near-term financing risk, but the company still has only $5.7M in cash against $17.5M in current debt maturities. Monitor the planned DrugSorb-ATR De Novo submission in early 2027 and progress on restoring Germany sales growth.

DirectionNeutral
Confidencehigh
Horizonweeks

CytoSorb

▼ Bearish Named in this 8-K
Impact
Phase
Approved / Commercialized
Time to market
Already on the market (CE-marked in Europe, FDA-cleared in US)
Next catalyst
None dated

What to watchWatch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.

Price Chart

Loading chart...

Executive Summary

CytoSorbents reported Q3 2026 revenue of $9.7M (+3% YoY) and a net loss of $1.8M ($0.58/share), improving from a $3.2M loss in Q3 2025. The company achieved operating cash flow breakeven (excluding restructuring payments), a key milestone, while advancing DrugSorb-ATR toward a planned De Novo submission in early 2027.

Key Financial Metrics

EPS (Adj.)
−$0.48
GAAP: $-0.58
Revenue
$9.7M
est $9.9M · -1.7% · +2.6% YoY
Gross Margin
75.3%

Key Facts

  • Q3 2026 revenue $9.7M, up 3% from $9.5M in Q3 2025
  • Gross margin improved to 75% from 70% a year ago
  • Operating loss improved 59% to $1.2M from $2.9M
  • Net loss improved 42% to $1.8M ($0.58/share) from $3.2M ($1.01/share)
  • Generated positive operating cash flow of ~$43,000, excluding $251,000 restructuring payments
  • Cash and equivalents $5.7M at Sept 30, 2026, down from $5.9M at June 30, 2026
  • Planned DrugSorb-ATR De Novo submission in early 2027; real-world data showing 37% relative reduction in severe bleeding
  • Germany sales declined 20% YoY, representing 24% of quarterly sales
  • Distributor and strategic partner sales grew 18% YoY and 10% sequentially

Financial Impact

Revenue $9.7M, net loss $1.8M, operating cash flow ~$43K positive

revenuegross marginoperating lossnet lossoperating cash flow

Risk Factors

  • Cash position of $5.7M is low relative to $17.5M in current debt maturities
  • Germany sales declined 20% YoY; recovery depends on new sales hires becoming productive
  • DrugSorb-ATR regulatory timeline subject to FDA review and potential delays
  • Stockholders' deficit of $2.3M indicates negative equity position

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000929638-26-004267
Document: a8k.htm0000929638-26-004267
Document: 0000929638-26-004267-index-headers.html0000929638-26-004267
Document: 0000929638-26-004267-index.html0000929638-26-004267
Document: 0000929638-26-004267.txt0000929638-26-004267
8-K Data (Synthetic)0000929638-26-004267

Track record

12 reports on CTSO

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.94% at T+60 after the Aug 6, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 20, 20261d ago 424B5 Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
  2. Nov 20, 20261d ago 8-K Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
  3. Nov 19, 20263d ago 8-K/A Neutral 4/10 Entry $5.13 Now $4.16 −18.91% settles Feb 18
  4. Nov 17, 20265d ago NT 10-Q Neutral 4/10 Entry $4.52 Now $4.16 −7.96% settles Feb 16
  5. Nov 12, 20269d ago Press Release Neutral 4/10 Entry $4.87 Now $4.16 −14.58% settles Feb 11
  6. Nov 12, 20269d ago 8-K Neutral 5/10 Viewing No price data
  7. Sep 23, 20268w ago 8-K Mixed 5/10 Entry $4.91 Now $4.16 −15.27% settles Dec 17
  8. Aug 6, 202615w ago Press Release Bearish 6/10 Entry $0.3600 to $0.2270 Now $4.16 −1055.56% ▲ +36.94% +34.68% vs SPY
  9. Jun 25, 202621w ago DEFA14A Neutral 3/10 Entry $0.3620 to $0.2660 Now $4.16 +1049.17% ▼ −26.52% −32.61% vs SPY
  10. Jun 16, 202622w ago Insider Cluster Bullish 6/10 Entry $0.5189 to $0.3205 Now $4.16 +701.70% ▼ −38.23% −40.10% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Mon (26h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026